解毒剂经骨内给药的系统评价
该系统评价检索了截至2016年6月30日的多个数据库,纳入47篇文献(46篇文章和1篇摘要),描述13种解毒剂的骨内给药。证据包括1篇病例系列和21篇病例报告(共26例患者)以及25项动物实验。人类病例报告提示骨内使用阿托品、地西泮、羟钴胺、胰岛素、脂肪乳剂、亚甲蓝、酚妥拉明、凝血酶原复合物浓缩物和碳酸氢钠的结局良好;唯一报告的不良事件是骨内给予纳洛酮后出现室性心动过速。动物实验显示骨内给予脂肪乳剂和羟钴胺分别改善布比卡因中毒大鼠和氰化物中毒猪的生存率,且阿托品、氯化钙、50%葡萄糖、地西泮、亚甲蓝、解磷定和碳酸氢钠的骨内与静脉给药生物利用度相当。作者认为,尽管证据质量低,当静脉通路不可用时,骨内通路是中毒复苏中解毒治疗的一个潜在选择。
要点
- 该系统评价纳入47篇文献,描述13种解毒剂的骨内给药,其中人类证据仅26例患者(1篇病例系列和21篇病例报告),其余为25项动物实验。
- 人类病例报告提示骨内使用阿托品、地西泮、羟钴胺、胰岛素、脂肪乳剂、亚甲蓝、酚妥拉明、凝血酶原复合物浓缩物和碳酸氢钠的结局良好。
- 唯一报告的不良事件是骨内给予纳洛酮后出现室性心动过速。
- 动物实验显示骨内给予脂肪乳剂和羟钴胺分别改善布比卡因中毒大鼠和氰化物中毒猪的生存率;阿托品、氯化钙、50%葡萄糖、地西泮、亚甲蓝、解磷定和碳酸氢钠的骨内与静脉给药生物利用度相当。
- 乙酰半胱氨酸、甲吡唑和地高辛特异性抗体片段等常见解毒剂尚未有骨内给药的研究或报告。
适用人群与场景
- 适用于中毒患者需紧急解毒治疗但静脉通路不易建立时,场景包括急诊科、复苏情境(如心脏骤停、烧伤、脱水、癫痫、失血性休克或未分化休克)。
- 纳入的研究对象包括志愿者研究、中毒患者或其他复苏情境的患者,以及动物实验;排除体外研究。
研究设计与关键结果
- 系统评价共纳入47篇文献(46篇文章和1篇摘要),描述13种解毒剂的骨内给药;包括1篇病例系列和21篇病例报告(共26例患者)以及25项动物实验。
- 其中7篇人类病例报告和4项动物实验专门报告了中毒时解毒剂的骨内使用。
- 人类病例报告提示骨内使用阿托品、地西泮、羟钴胺、胰岛素、脂肪乳剂、亚甲蓝、酚妥拉明、凝血酶原复合物浓缩物和碳酸氢钠的结局良好;临床结局因所用解毒剂而异。
- 唯一报告的不良事件是骨内给予纳洛酮后出现室性心动过速。
- 动物实验显示,骨内给予脂肪乳剂在布比卡因中毒大鼠中改善生存率,骨内给予羟钴胺在氰化物中毒猪中改善生存率。
- 动物数据提示阿托品、氯化钙、50%葡萄糖、地西泮、亚甲蓝、解磷定和碳酸氢钠的骨内与静脉给药生物利用度相当。
- 关于骨内给予碳酸氢钠后脂肪栓塞的不良事件报告存在矛盾,原因是各研究间肺部检查时间存在显著异质性。
证据类型、等级与局限
- 证据类型为系统评价,纳入文献包括病例系列、病例报告和动物实验。
- 作者结论指出,支持中毒时经骨内途径给予解毒剂的证据稀缺,多数证据为病例报告和动物实验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,尽管证据质量低,当静脉通路不可用时,骨内通路是中毒复苏中解毒治疗的一个潜在选择。
- 乙酰半胱氨酸、甲吡唑和地高辛特异性抗体片段等常见解毒剂尚未有骨内给药的研究或报告。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
CONTEXT: Intraosseous (IO) access is an established route of administration in resuscitation situations. Patients with serious poisoning presenting to the emergency department may require urgent antidote therapy. However, intravenous (IV) access is not always readily available.
OBJECTIVE: This study reviews the current evidence for IO administration of antidotes that could be used in poisoning. The primary outcome was mortality as a surrogate of efficacy. Secondary outcomes included hemodynamic variables, electrocardiographic variables, neurological status, pharmacokinetics outcomes, and adverse effects as defined by each article.
METHODS: A medical librarian created a systematic search strategy for Medline, subsequently translated to Embase, BIOSIS, PubMed, Web of Science, Cochrane, Database of Abstracts of Reviews of Effects (DARE), and the CENTRAL clinical trial register, all of which we searched from inception to 30 June 2016. Interventions included IO administration of selected antidotes. Articles included volunteer studies, poisoning, or other resuscitation contexts such as cardiac arrest, burns, dehydration, seizure, hemorrhagic shock, or undifferentiated shock. We considered all human studies and animal experiments to the exception of in vitro studies. Two reviewers independently selected studies, and a third adjudicated in case of disagreement. Three reviewers extracted all relevant data. Three reviewers evaluated the risk of bias and quality of the articles using specific scales according to each type of study design.
RESULTS: A total of 47 publications (46 articles and one abstract) met our inclusion criteria and described IO administration of 13 different antidotes. These included one case series and 21 case reports describing 26 patients, and 25 animal experiments. Of those, seven human case reports and four animal experiments specifically reported the use of antidotes in poisoning. Human case reports suggested favorable outcomes with IO use of atropine, diazepam, hydroxocobalamin, insulin, lipid emulsion, methylene blue, phentolamine, prothrombin complex concentrate, and sodium bicarbonate. Clinical outcomes varied according to the antidote used. The only reported adverse event was ventricular tachycardia following IO naloxone. Regarding the animal experiments, IO administration of lipid emulsion and of hydroxocobalamin showed improved survival in bupivacaine-poisoned rats and in cyanide-intoxicated swine, respectively. Animal data also suggested an equivalent bio-availability between IO and IV administration for atropine, calcium chloride, dextrose 50%, diazepam, methylene blue, pralidoxime, and sodium bicarbonate. Adverse effect reporting of fat emboli after IO administration of sodium bicarbonate, for example, was conflicting due to the significant heterogeneity in the timing of lung examination across studies.
CONCLUSION: The evidence supporting the use of IO route for the administration of antidotes in a context of poisoning is scarce. The majority of the evidence consists of case reports and animal experiments. Common antidotes such as acetylcysteine, fomepizole, and digoxin-specific antibody fragments have not been studied or reported with the use of the IO route. Despite the low-quality evidence available, IO access is a potential option for antidotal treatments in toxicological resuscitation when IV access is unavailable.
参考来源
- Elliott A, Dubé PA, Cossette-Côté A, et al. Intraosseous administration of antidotes - a systematic review. Clin Toxicol (Phila). 2017. PMID: 28644688. doi:10.1080/15563650.2017.1337122
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。